MesaGreen Pharmaceutical Company is a virtual animal-health pharmaceutical developer creating an at-home emergency treatment for breakthrough seizures in dogs. The Frederick company is developing its K9MGP product around an auto-injection system intended to deliver rapid rescue therapy, drawing on human drug-delivery experience and veterinary research. MesaGreen is a small veteran-owned business and a wholly owned subsidiary of Mesa Science Associates.
Investigational New Animal Drug Application (INAD)
registration
FDA Center for Veterinary Medicine regulatory development process
compliance_program
Veteran-Owned Small Business
certification
ISK Animal Health, LLCISK Animal Health develops animal-health medicines, including BRENDA™, a treatment for reducing clinical signs associated with acute pancreatitis in dogs. Its fuzapladib sodium hydrate works through a distinct mechanism that blocks inflammatory-cell adhesion, and the product received manufacturing and marketing approval in Japan in 2018.CONCORD TOWNSHIP, OH
JopeBorn from veterinarian Christine’s search for help after her dog Pepsi developed severe joint problems, Jope makes science-backed supplements for dogs and cats. Co-founded by practicing veterinarians Christine and Jeremy, the company formulates products such as its UC-II collagen hip-and-joint chews and GB-01 gut-balance capsules after reviewing clinical research, with manufacturing in the USA and third-party testing for every batch.
AveriaFounded by Yury and Ekaterina after they opened a veterinary clinic for their own dog, Averia makes smart GPS collars and connected accessories that help owners monitor a dog’s location, activity, and safety. The company grew out of veterinary practice and six years of research and development, pairing its collar hardware with an app for global tracking, virtual Safe Zones, and shared care. Averia says its collar was built from scratch six times before the team was satisfied with the result.NEW YORK, NY
LifePulse CorporationLifePulse Corporation develops and manufactures its US-engineered Intellipulse® platform to deliver therapeutics directly into cells, with a focus on targeted oncology in human and veterinary medicine. Founded by Gary Strange, the Tampa Bay company builds on more than three decades of research, $35 million in non-dilutive funding, and over 100 issued patents. Its animal-health division has treated hundreds of dogs, cats, and horses since 2022, while its human-health program is advancing toward pancreatic-tumor trials.NEW YORK, NY